13 results
8-K/A
EX-99.1
ELTX
Elicio Therapeutics Inc.
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders
8-K/A
EX-99.2
ELTX
Elicio Therapeutics Inc.
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
by such holder are then convertible. Certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events
425
ELTX
Elicio Therapeutics Inc.
23 May 23
Business combination disclosure
8:42pm
, such as the six months to a year (plus additional time to resolve any potential litigation) it would take to dissolve the Company, wind down its business
8-K
ELTX
Elicio Therapeutics Inc.
23 May 23
Other Events
8:40pm
to resolve any potential litigation) it would take to dissolve the Company, wind down its business, run a third-party process for a sale of its assets
424B3
ELTX
Elicio Therapeutics Inc.
28 Apr 23
Prospectus supplement
4:07pm
made by Angion related to wind down activities of Angion associated with the termination of its research and development activities (including
CORRESP
6kcj e9xejws07j46
13 Apr 23
Correspondence with SEC
12:00am
S-4/A
exnbrqiz
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
EX-10.26
bqizg219k xth
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
424B3
35vvpx uvtu3r
24 May 22
Prospectus supplement
4:01pm
S-3
pn1ovkz9m6ttijgz
16 May 22
Shelf registration
5:23pm
- Prev
- 1
- Next